PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Dec 19, 2018

byncaipen

Transplants

ProtoKinetix Releases First in a Series of Scientific Update Videos

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the first in a series of informational videos by the Principal Investigators in each field currently...Read more

Sep 28, 2018

byncaipen

Transplants

ProtoKinetix Begins Cardiovascular Research

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences. Dr. Thomas...Read more

Sep 04, 2018

byncaipen

Ophthalmology | Transplants

ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) President and Chief Executive Officer Clarence Smith is pleased at the progress of the health care applications projects the Company...Read more

Aug 10, 2018

byncaipen

Ophthalmology

ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due...Read more

Jun 13, 2018

byncaipen

Biomanufacturing

ProtoKinetix' AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to announce that it has executed a Material Transfer Agreement (MTA) with a reputed biotechnology company having a...Read more

Jan 10, 2018

byncaipen

Biomanufacturing | Transplants

ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP® on Monoclonal Antibody Production and Bone Marrow Recovery

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under...Read more

Nov 16, 2017

byncaipen

Biomanufacturing

The Effects of ProtoKinetix' Anti-Aging Glycopeptide (AAGP®) on Immune Cell Banking and Functions Relevant to Immunotherapy

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update on immune cell banking and functions relevant to immunotherapy using AAGP® in collaboration...Read more

Oct 17, 2017

byncaipen

Biomanufacturing | Transplants

Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery

Belpre, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use...Read more

Jun 05, 2017

byncaipen

Biomanufacturing

ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP® in Immune Cell Cryopreservation Testing

St. Marys, West Virginia ProtoKinetix, Incorporated (PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) and Proactive Immune Sciences (www.proactiveimmunesciences.com) today announce that they have entered into a joint research collaboration. The goal of...Read more

May 24, 2017

byncaipen

Ophthalmology | Transplants

ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP®

About ProtoKinetix, Incorporated ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.